Concepedia

Katie Snead

KS

Statistics

Publications

4

Citations

356

H-Index

4

Active since

2015

Affiliations

Seagen (United States)(Current)

Katie Snead is an author at Seagen (United States) specializing in oncology, immune checkpoint inhibitors, and cancer immunotherapy.

Publications per year

2015–2023

4

Publications

4

A Comprehensive Analysis of Replicative Lifespan in 4,698 Single-Gene Deletion Strains Uncovers Conserved Mechanisms of Aging

Mark A. McCormick, Joe R. Delaney, Mitsuhiro Tsuchiya et al. · Cell Metabolism · 2015 · 270 citations · Full text

Education, Genetics, Molecular Genetics +12

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models

Elizabeth Gray, Michelle Ulrich, Angela Epp et al. · Journal for ImmunoTherapy of Cancer · 2023 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers

Bernard A. Liu, Devra J. Olson, Katie Snead et al. · Cancer Research · 2020 · 30 citations

Medicine, Oncology, Pharmacology +16

1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors

Devra J. Olson, Patrick Younan, Bernard A. Liu et al. · Regular and Young Investigator Award Abstracts · 2022 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17

1–4 of 4